Voronoi Co. Ltd.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid ar… Read more
Voronoi Co. Ltd. - Asset Resilience Ratio
Voronoi Co. Ltd. (310210) has an Asset Resilience Ratio of 59.61% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Voronoi Co. Ltd.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Voronoi Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩59.34 Billion | 59.61% |
| Total Liquid Assets | ₩59.34 Billion | 59.61% |
Asset Resilience Insights
- Very High Liquidity: Voronoi Co. Ltd. maintains exceptional liquid asset reserves at 59.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Voronoi Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Voronoi Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Voronoi Co. Ltd. (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Voronoi Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 73.24% | ₩53.95 Billion | ₩73.66 Billion | +9.58pp |
| 2023-12-31 | 63.66% | ₩60.25 Billion | ₩94.65 Billion | -11.98pp |
| 2022-12-31 | 75.63% | ₩48.37 Billion | ₩63.95 Billion | +30.16pp |
| 2021-12-31 | 45.48% | ₩18.26 Billion | ₩40.16 Billion | -1.56pp |
| 2020-12-31 | 47.03% | ₩22.44 Billion | ₩47.71 Billion | +43.29pp |
| 2019-12-31 | 3.74% | ₩1.14 Billion | ₩30.59 Billion | -- |